The OncoAlert Network 🚨
@oncoalert.bsky.social
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
www.OncoAlert360.com
www.OncoAlert360.com
Pinned
Colleagues, the Complete #ESMO25 OncoAlert Newsletter is coming Oct 27‼️ GET IT HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
Straight from #UromigosLive 2025
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
November 8, 2025 at 8:09 PM
Straight from #UromigosLive 2025
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the Uromigos discuss Combinations in Heavily Treated #KidneyCancer Patients
Tom wonders if it is time to say that this second generation check points have not been that impressive
Give them a quick listen
buff.ly/EV0pcsN
Tom wonders if it is time to say that this second generation check points have not been that impressive
Give them a quick listen
buff.ly/EV0pcsN
Uromigos (@Uromigos) on X
A Great First Day of #UromigosLive 2025🇺🇸 On our Out and about in Nashville Series, @tompowles1 and @brian_rini Discuss #KidneyCancer Combination Treatments and give us a little history on the…
buff.ly
November 8, 2025 at 5:30 PM
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the Uromigos discuss Combinations in Heavily Treated #KidneyCancer Patients
Tom wonders if it is time to say that this second generation check points have not been that impressive
Give them a quick listen
buff.ly/EV0pcsN
Tom wonders if it is time to say that this second generation check points have not been that impressive
Give them a quick listen
buff.ly/EV0pcsN
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the @Uromigos Tom and Briandiscuss Combinations in Heavily Treated #KidneyCancer
Here they KEYMAKER U03 in KidneyCancer
Give them a quick listen and if you want to dive deeper, here is the full video
buff.ly/EV0pcsN
Here they KEYMAKER U03 in KidneyCancer
Give them a quick listen and if you want to dive deeper, here is the full video
buff.ly/EV0pcsN
Uromigos (@Uromigos) on X
A Great First Day of #UromigosLive 2025🇺🇸 On our Out and about in Nashville Series, @tompowles1 and @brian_rini Discuss #KidneyCancer Combination Treatments and give us a little history on the…
buff.ly
November 8, 2025 at 3:00 PM
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the @Uromigos Tom and Briandiscuss Combinations in Heavily Treated #KidneyCancer
Here they KEYMAKER U03 in KidneyCancer
Give them a quick listen and if you want to dive deeper, here is the full video
buff.ly/EV0pcsN
Here they KEYMAKER U03 in KidneyCancer
Give them a quick listen and if you want to dive deeper, here is the full video
buff.ly/EV0pcsN
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the @Uromigos @tompowles1 and @brian_rini discuss Combinations in Heavily Treated #KidneyCancer Patients
Give them a quick listen and if you want to dive deeper, here is the full video
Give them a quick listen and if you want to dive deeper, here is the full video
Uromigos Live 2025 Kidney Cancer Combination Treatments
During the #UromigosLive Meeting and in our walking through Nashville Series, Dr. Brian Rini and Dr. Tom Powles give us a breakdown of #kidneycancer Combination Treatments and a little bit of…
youtu.be
November 8, 2025 at 1:45 PM
Here at #UromigosLive 2025 in Nashville and have the pleasure to have the @Uromigos @tompowles1 and @brian_rini discuss Combinations in Heavily Treated #KidneyCancer Patients
Give them a quick listen and if you want to dive deeper, here is the full video
Give them a quick listen and if you want to dive deeper, here is the full video
Uromigos Live 2025 Kidney Cancer Combination Treatments with Brian Rini and Tom Powles on our Out and about in Nashville Series WATCH HERE 👉 youtu.be/_blk6T4HFOk
Uromigos Live 2025 Kidney Cancer Combination Treatments
During the #UromigosLive Meeting and in our walking through Nashville Series, Dr. Brian Rini and Dr. Tom Powles give us a breakdown of #kidneycancer Combination Treatments and a little bit of…
youtu.be
November 7, 2025 at 9:21 PM
Uromigos Live 2025 Kidney Cancer Combination Treatments with Brian Rini and Tom Powles on our Out and about in Nashville Series WATCH HERE 👉 youtu.be/_blk6T4HFOk
LIVE FROM NASHVILLE at #UromigosLive ⭐️Here are Tom & Brian to tell us more on what to expect during these coming 2 days and beyond. 👉 youtu.be/lyPBTkCOZ1E
#UromigosLive 2025 :Tom & Brian to tell us more on what to expect during the event
The Annual #UromigosLive is LIVE and coming to you from Nashville TN. Our Hosts the Uromigos (Tom Powles and Brian Rini) Guide us through what is to come these days.
youtu.be
November 7, 2025 at 5:06 PM
LIVE FROM NASHVILLE at #UromigosLive ⭐️Here are Tom & Brian to tell us more on what to expect during these coming 2 days and beyond. 👉 youtu.be/lyPBTkCOZ1E
Dear Colleagues in #ESMO25
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
November 7, 2025 at 1:47 PM
Dear Colleagues in #ESMO25
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
Join us for a discussion on rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD
November 7, 2025 at 1:41 PM
Join us for a discussion on rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD
A warm invite to join a live, free interactive webinar on November 4, 2025, at CET REGISTER👉
us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm @grimm_mo will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive #ProstateCancer (mHSPC).
us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm @grimm_mo will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive #ProstateCancer (mHSPC).
November 4, 2025 at 11:39 AM
A warm invite to join a live, free interactive webinar on November 4, 2025, at CET REGISTER👉
us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm @grimm_mo will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive #ProstateCancer (mHSPC).
us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm @grimm_mo will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive #ProstateCancer (mHSPC).
Starting THIS FRIDAY November 7, 2025
DIRECT from NASHVILLE🇺🇸 #UromigosLIVE
WE ARE THERE 🚨Stay Tuned for Coverage!!
Presenting Our Ambassadors
&
OncoAlert 🚨GU Faculty
DIRECT from NASHVILLE🇺🇸 #UromigosLIVE
WE ARE THERE 🚨Stay Tuned for Coverage!!
Presenting Our Ambassadors
&
OncoAlert 🚨GU Faculty
November 4, 2025 at 10:57 AM
Starting THIS FRIDAY November 7, 2025
DIRECT from NASHVILLE🇺🇸 #UromigosLIVE
WE ARE THERE 🚨Stay Tuned for Coverage!!
Presenting Our Ambassadors
&
OncoAlert 🚨GU Faculty
DIRECT from NASHVILLE🇺🇸 #UromigosLIVE
WE ARE THERE 🚨Stay Tuned for Coverage!!
Presenting Our Ambassadors
&
OncoAlert 🚨GU Faculty
Join Vérane Achard and Bertrand Timbal for this Manuscript2Practice series on postoperative #ProstateCancer recurrence 👉 mirrorsmed.org/m2p-postoper...
brought to you by our collaborators at Mirrors of Medicine.
brought to you by our collaborators at Mirrors of Medicine.
November 1, 2025 at 10:37 AM
Join Vérane Achard and Bertrand Timbal for this Manuscript2Practice series on postoperative #ProstateCancer recurrence 👉 mirrorsmed.org/m2p-postoper...
brought to you by our collaborators at Mirrors of Medicine.
brought to you by our collaborators at Mirrors of Medicine.
Reposted by The OncoAlert Network 🚨
🚨New Simply Oncology Podcast👻
We discuss SABR in met #prostatecancer with the superb @alison-tree.bsky.social
🗣️ TRAP study which ⬆️ time to next treatment by 6 months when SABR was used for sites of oligoprogression⚡️
Spookily good 🧟♂️
@oncoalert.bsky.social @radiotherapy.bsky.social @icr.ac.uk
We discuss SABR in met #prostatecancer with the superb @alison-tree.bsky.social
🗣️ TRAP study which ⬆️ time to next treatment by 6 months when SABR was used for sites of oligoprogression⚡️
Spookily good 🧟♂️
@oncoalert.bsky.social @radiotherapy.bsky.social @icr.ac.uk
October 31, 2025 at 7:45 AM
🚨New Simply Oncology Podcast👻
We discuss SABR in met #prostatecancer with the superb @alison-tree.bsky.social
🗣️ TRAP study which ⬆️ time to next treatment by 6 months when SABR was used for sites of oligoprogression⚡️
Spookily good 🧟♂️
@oncoalert.bsky.social @radiotherapy.bsky.social @icr.ac.uk
We discuss SABR in met #prostatecancer with the superb @alison-tree.bsky.social
🗣️ TRAP study which ⬆️ time to next treatment by 6 months when SABR was used for sites of oligoprogression⚡️
Spookily good 🧟♂️
@oncoalert.bsky.social @radiotherapy.bsky.social @icr.ac.uk
THE #ESMO25 COMPLETE Newsletter by OncoAlert 🚨MONDAY Nov 3rd is the FINAL DAY TO GET IT‼️ TO GET IT REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
October 31, 2025 at 2:43 PM
THE #ESMO25 COMPLETE Newsletter by OncoAlert 🚨MONDAY Nov 3rd is the FINAL DAY TO GET IT‼️ TO GET IT REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
Our #OncoAlertAF 🚨Colleague Nicholas Hornstein 🇺🇸 of @NorthwellHealth with TOP picks of #GIOncology Presented at #ESMO25 🇩🇪 👉 youtu.be/tVaVJ7pg50I
for the OncoAlert TOP3 Series post ESMO 2025, more to come..
✅NICHE2
✅STELLAR 303
for the OncoAlert TOP3 Series post ESMO 2025, more to come..
✅NICHE2
✅STELLAR 303
TOP 3 Highlights in GI Oncology for #ESMO25 by Dr. Nicholas Hornstein
Our OncoAlert Faculty Dr. Nicholas Hornstein from the Northwell Health shares his Top GI Oncology picks from ESMO 2025 in Berlin, breaking down the most impactful GI trials shaping the field…
youtu.be
October 31, 2025 at 2:32 PM
Our #OncoAlertAF 🚨Colleague Nicholas Hornstein 🇺🇸 of @NorthwellHealth with TOP picks of #GIOncology Presented at #ESMO25 🇩🇪 👉 youtu.be/tVaVJ7pg50I
for the OncoAlert TOP3 Series post ESMO 2025, more to come..
✅NICHE2
✅STELLAR 303
for the OncoAlert TOP3 Series post ESMO 2025, more to come..
✅NICHE2
✅STELLAR 303
The OncoAlert 🚨 TOP STACK: IMvigor011
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
October 31, 2025 at 10:00 AM
The OncoAlert 🚨 TOP STACK: IMvigor011
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
Our Collaborators at @mirrorsofmedicine.bsky.social would like to Invite you to Join The Global Forum on GU Oncology info here👉 gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
October 30, 2025 at 2:41 PM
Our Collaborators at @mirrorsofmedicine.bsky.social would like to Invite you to Join The Global Forum on GU Oncology info here👉 gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
Reposted by The OncoAlert Network 🚨
🚨New Simply Oncology episode on using CBM and the gut microbiome to influence IO in #renalcancer
Could CBM 588💊 be one of the good 🦠 to unlock our gut biome?
Prof Monty Pal is amazing - as always!
@oncoalert.bsky.social @kidneycancer.bsky.social @ikccorg.bsky.social @eururoloncol.bsky.social
Could CBM 588💊 be one of the good 🦠 to unlock our gut biome?
Prof Monty Pal is amazing - as always!
@oncoalert.bsky.social @kidneycancer.bsky.social @ikccorg.bsky.social @eururoloncol.bsky.social
October 24, 2025 at 6:26 AM
🚨New Simply Oncology episode on using CBM and the gut microbiome to influence IO in #renalcancer
Could CBM 588💊 be one of the good 🦠 to unlock our gut biome?
Prof Monty Pal is amazing - as always!
@oncoalert.bsky.social @kidneycancer.bsky.social @ikccorg.bsky.social @eururoloncol.bsky.social
Could CBM 588💊 be one of the good 🦠 to unlock our gut biome?
Prof Monty Pal is amazing - as always!
@oncoalert.bsky.social @kidneycancer.bsky.social @ikccorg.bsky.social @eururoloncol.bsky.social
Our OncoAlert 🚨Faculty @weoncologists.bsky.social 🇺🇸with his TOP picks of #ProstateCancer Trials. WATCH HERE 👉 youtu.be/u1ehzE_lFtY
Trials were Presented at #ESMO25 🇩🇪 and we have included them as part of our OncoAlert TOP3 Series post ESMO 2025, more to come..
✅EMBARK
✅CAPItello-281
✅PETRANHA
Trials were Presented at #ESMO25 🇩🇪 and we have included them as part of our OncoAlert TOP3 Series post ESMO 2025, more to come..
✅EMBARK
✅CAPItello-281
✅PETRANHA
TOP3 Highlights for #ProstateCancer from #ESMO25 by Dr. Gil Morgan
YouTube video by OncoAlert 360
youtu.be
October 30, 2025 at 12:38 PM
Our OncoAlert 🚨Faculty @weoncologists.bsky.social 🇺🇸with his TOP picks of #ProstateCancer Trials. WATCH HERE 👉 youtu.be/u1ehzE_lFtY
Trials were Presented at #ESMO25 🇩🇪 and we have included them as part of our OncoAlert TOP3 Series post ESMO 2025, more to come..
✅EMBARK
✅CAPItello-281
✅PETRANHA
Trials were Presented at #ESMO25 🇩🇪 and we have included them as part of our OncoAlert TOP3 Series post ESMO 2025, more to come..
✅EMBARK
✅CAPItello-281
✅PETRANHA
The OncoAlert TOP STACK: DESTINY Breast 09
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
October 30, 2025 at 10:00 AM
The OncoAlert TOP STACK: DESTINY Breast 09
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic #BreastCancer
www.nejm.org/doi/10.1056/...
combination of trastuzumab deruxtecan and pertuzumab yielded a substantial progression-free survival benefit without new safety concerns
www.nejm.org/doi/10.1056/...
combination of trastuzumab deruxtecan and pertuzumab yielded a substantial progression-free survival benefit without new safety concerns
October 30, 2025 at 9:33 AM
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic #BreastCancer
www.nejm.org/doi/10.1056/...
combination of trastuzumab deruxtecan and pertuzumab yielded a substantial progression-free survival benefit without new safety concerns
www.nejm.org/doi/10.1056/...
combination of trastuzumab deruxtecan and pertuzumab yielded a substantial progression-free survival benefit without new safety concerns
You are warmly invited to join a live, free interactive webinar on November 4, 2025, at 18:00 CET REGISTER👉 us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive prostate cancer (mHSPC).
Fred Saad and Marc-Oliver Grimm will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive prostate cancer (mHSPC).
October 29, 2025 at 2:46 PM
You are warmly invited to join a live, free interactive webinar on November 4, 2025, at 18:00 CET REGISTER👉 us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive prostate cancer (mHSPC).
Fred Saad and Marc-Oliver Grimm will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive prostate cancer (mHSPC).
LEAP 012 Update/ Source MERCK
Merck and Eisai announced results from the Phase 3 LEAP-012 trial evaluating the combination of pembrolizumab and lenvatinib TACE in unresectable, non-metastatic hepatocellular carcinoma.
did not achieve statistical significance for OS
www.merck.com/news/merck-a...
Merck and Eisai announced results from the Phase 3 LEAP-012 trial evaluating the combination of pembrolizumab and lenvatinib TACE in unresectable, non-metastatic hepatocellular carcinoma.
did not achieve statistical significance for OS
www.merck.com/news/merck-a...
October 29, 2025 at 12:07 PM
LEAP 012 Update/ Source MERCK
Merck and Eisai announced results from the Phase 3 LEAP-012 trial evaluating the combination of pembrolizumab and lenvatinib TACE in unresectable, non-metastatic hepatocellular carcinoma.
did not achieve statistical significance for OS
www.merck.com/news/merck-a...
Merck and Eisai announced results from the Phase 3 LEAP-012 trial evaluating the combination of pembrolizumab and lenvatinib TACE in unresectable, non-metastatic hepatocellular carcinoma.
did not achieve statistical significance for OS
www.merck.com/news/merck-a...
UPDATE: LITESPARK-011
NEWS FROM INDUSTRY/ Source MERCK
Merck & Eisai announce LITESPARK-011 trial met its 1ry endpoint, showing belzutifan + lenvatinib significantly improved PFS 📈 Vs with cabozantinib in adv RCC who progressed after anti–PD-1/L1 therapy. #KidneyCancer
www.merck.com/news/merck-a...
NEWS FROM INDUSTRY/ Source MERCK
Merck & Eisai announce LITESPARK-011 trial met its 1ry endpoint, showing belzutifan + lenvatinib significantly improved PFS 📈 Vs with cabozantinib in adv RCC who progressed after anti–PD-1/L1 therapy. #KidneyCancer
www.merck.com/news/merck-a...
October 28, 2025 at 11:25 AM
UPDATE: LITESPARK-011
NEWS FROM INDUSTRY/ Source MERCK
Merck & Eisai announce LITESPARK-011 trial met its 1ry endpoint, showing belzutifan + lenvatinib significantly improved PFS 📈 Vs with cabozantinib in adv RCC who progressed after anti–PD-1/L1 therapy. #KidneyCancer
www.merck.com/news/merck-a...
NEWS FROM INDUSTRY/ Source MERCK
Merck & Eisai announce LITESPARK-011 trial met its 1ry endpoint, showing belzutifan + lenvatinib significantly improved PFS 📈 Vs with cabozantinib in adv RCC who progressed after anti–PD-1/L1 therapy. #KidneyCancer
www.merck.com/news/merck-a...
LITESPARK-022 Update
NEWS FROM INDUSTRY Source: MERCK
Merck announced positive topline results from LITESPARK-022 trial, showing that pembrolizumab combined with belzutifan significantly improved DFS 📈 Vs pembrolizumab alone in patients with RCC #KidneyCancer
www.merck.com/news/merck-a...
NEWS FROM INDUSTRY Source: MERCK
Merck announced positive topline results from LITESPARK-022 trial, showing that pembrolizumab combined with belzutifan significantly improved DFS 📈 Vs pembrolizumab alone in patients with RCC #KidneyCancer
www.merck.com/news/merck-a...
October 28, 2025 at 11:19 AM
LITESPARK-022 Update
NEWS FROM INDUSTRY Source: MERCK
Merck announced positive topline results from LITESPARK-022 trial, showing that pembrolizumab combined with belzutifan significantly improved DFS 📈 Vs pembrolizumab alone in patients with RCC #KidneyCancer
www.merck.com/news/merck-a...
NEWS FROM INDUSTRY Source: MERCK
Merck announced positive topline results from LITESPARK-022 trial, showing that pembrolizumab combined with belzutifan significantly improved DFS 📈 Vs pembrolizumab alone in patients with RCC #KidneyCancer
www.merck.com/news/merck-a...
Our Collaborators at @high5md have gathered top international experts in Lung Cancer
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!
October 24, 2025 at 1:43 PM
Our Collaborators at @high5md have gathered top international experts in Lung Cancer
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!